share this article!

The stock price of Charles River Laboratories, (NYSE: CRL) a company that offers clinical laboratory, gene therapy, and cell therapy services for the pharmaceuticals industry, has seen a 13% rise over the last twenty-one trading days. The company recently completed the acquisition of Vigene Biosciences, a contract manufacturer specializing in gene delivery solutions. This acquisition appears to be good for Charles River, given that it can now offer end-to-end gene-modified cell therapy solutions. Vigene’s revenue contribution is estimated to be north of $30 million for Charles River in 2021, and it is expected to grow at 25% annually over the next five years. [1]

However, now that CRL stock has seen a rise of 13% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a strong chance of a rise in CRL stock over the next month. Out of 147 instances in the last ten years that CRL stock saw a twenty-one day rise of 13% or more, 100 of them resulted in CRL stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 100 out of 147, or about 68% chance of a rise in CRL stock over the coming month. See our analysis on Charles River Laboratories Stock Chances of Decline for more details.

Calculation of ‘Event Probability’ and ‘Chance of Rise’ using last ten year data

  1. After moving 1.7% or more over a five-day period, the stock rose in the next five days on 55% of the occasions.
  2. After moving 5.8% or more over a ten-day period, the stock rose in the next ten days on 55% of the occasions
  3. After moving 13.0% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 68% of the occasions.

Predict average return on Charles River Laboratories Stock Return: AI Predicts CRL Average and Excess Return After a Fall or Rise

Charles River Laboratories Stock Return (Recent) Comparison With Peers And S&P500

  • Five-Day Return: CRL highest at 1.7%; KW lowest at -2.6%
  • Ten-Day Return: CRL highest at 5.8%; CBZ lowest at 0.3%
  • Twenty-One Day Return: CRL highest at 13.0%; MGRC lowest at -3.9%

MORE FOR YOU

While CRL stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Heico vs AbbVie.

See all Trefis Featured Analyses and Download Trefis Data here

Read More

share this article!